Approximately 80% of breast cancers are classified as HR+/HER2− and are treated with adjuvant hormone therapies such as the selective estrogen receptor modulator (SERM) tamoxifen and aromatase inhibitors such as anastrozole [2]. This evidence concerns the gene ESR1 and breast cancer.